Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery or RFA versus continued sintilimab + bevacizumab after downstaging HCC from BCLC B/C to A
ChiCTR2300073889Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Time to treatment failure (TTF) and Adverse events. Started Jul 2023; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073889.